Rheumatology

NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia

Monday, July 26, 2021 - 2:00pm

WOBURN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the Journal of Pain Research.

Key Points: 
  • WOBURN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the Journal of Pain Research.
  • Note: The use of Quell for fibromyalgia is investigational and has not been cleared or approved by the U.S. Food and Drug Administration (FDA).
  • Fibromyalgia is a common form of chronic pain that is also accompanied by fatigue, sleep, cognitive and mood disturbances.
  • Quell is a wearable neurostimulation device indicated for treatment of lower extremity chronic pain.

Global Psoriatic Arthritis Epidemiology 10-year Forecasts 2020-2030 - ResearchAndMarkets.com

Monday, July 26, 2021 - 9:39am

The disease epidemiology covered in the report provides historical and forecasted Psoriatic Arthritis epidemiology segmented as the Prevalent cases of Psoriatic Arthritis, Diagnosed cases of Psoriatic Arthritis, Gender-specific cases of Psoriatic Arthritis, Age-specific cases of Psoriatic Arthritis and Severity-specific Prevalence of Psoriatic Arthritis.

Key Points: 
  • The disease epidemiology covered in the report provides historical and forecasted Psoriatic Arthritis epidemiology segmented as the Prevalent cases of Psoriatic Arthritis, Diagnosed cases of Psoriatic Arthritis, Gender-specific cases of Psoriatic Arthritis, Age-specific cases of Psoriatic Arthritis and Severity-specific Prevalence of Psoriatic Arthritis.
  • The report provides the segmentation of the Psoriatic Arthritis epidemiology by total prevalent cases of Psoriatic Arthritis in the 7MM.
  • The report provides the segmentation of the Psoriatic Arthritis epidemiology by age-specific cases of Psoriatic Arthritis in the 7MM.
  • The report provides the segmentation of the Psoriatic Arthritis epidemiology by the severity-specific prevalence of Psoriatic Arthritis in the 7MM.

Tryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Wednesday, July 21, 2021 - 12:00pm

The study is expected to be the world's first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia

Key Points: 
  • The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.
  • The Principal Investigator for the trial will be Kevin Boehnke, Ph.D., Research Investigator, University of Michigan Department of Anesthesiology.
  • Tryp expects to submit the Investigational New Drug (IND) application to the FDA for the Phase 2a clinical trial in 3Q 2021.
  • The company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively.

Global Juvenile Idiopathic Arthritis Clinical Trial Pipeline Research Report 2021-2025: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Wednesday, July 21, 2021 - 3:44pm

The "Global Juvenile Idiopathic Arthritis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Juvenile Idiopathic Arthritis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Juvenile Idiopathic Arthritis Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Juvenile Idiopathic Arthritis market.
  • It covers emerging therapies for Juvenile Idiopathic Arthritis in active clinical development stages including early and late stage clinical trials.
  • The report provides Juvenile Idiopathic Arthritis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Global Psoriatic Arthritis Clinical Trial Pipeline Research Report 2021: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Wednesday, July 21, 2021 - 2:34pm

The "Global Psoriatic Arthritis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Psoriatic Arthritis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Psoriatic Arthritis Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Psoriatic Arthritis market.
  • It covers emerging therapies for Psoriatic Arthritis in active clinical development stages including early and late stage clinical trials.
  • The report provides Psoriatic Arthritis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Global Ankylosing Spondylitis Clinical Trial Pipeline Research Report 2021: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Wednesday, July 21, 2021 - 2:24pm

The "Global Ankylosing Spondylitis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Ankylosing Spondylitis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Ankylosing Spondylitis Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Ankylosing Spondylitis market.
  • It covers emerging therapies for Ankylosing Spondylitis in active clinical development stages including early and late stage clinical trials.
  • The report provides Ankylosing Spondylitis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

HSS Research Reveals New Insights into Racial Disparities in Revision Total Knee Replacement

Wednesday, July 21, 2021 - 4:11pm

Now, researchers at Hospital for Special Surgery (HSS) have examined racial disparities separately for aseptic and septic revision total knee replacement using data from three large states.

Key Points: 
  • Now, researchers at Hospital for Special Surgery (HSS) have examined racial disparities separately for aseptic and septic revision total knee replacement using data from three large states.
  • In addition to being Black, other factors associated with a higher risk of septic revision total knee replacement were diabetes, obesity, renal disease, COPD, inflammatory arthritis, surgical site complications, Medicaid insurance and low hospital total knee replacement volume.
  • Similarly, for aseptic revision, additional risk factors were male sex, workers' compensation insurance and low hospital total knee replacement volume.
  • Parks and colleagues are currently conducting further research to look for a relationship between revision total knee replacement risk, hospital volume and annual volume by surgeon to see if they can learn more about racial disparities.

Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

Wednesday, July 21, 2021 - 1:45pm

Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.

Key Points: 
  • Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.
  • Tryp will be collaborating with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School, a leading center in chronic pain research.
  • The upcoming Phase 2a trial is believed to be the world's first Phase 2 trial utilizing psilocybin for a chronic pain indication.
  • The clinical trial seeks to apply the neuroplasticity benefits of psilocybin to address the source of pain signals in fibromyalgia patients.

Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

Wednesday, July 21, 2021 - 1:45pm

NEW YORK, July 21, 2021 /PRNewswire/ -- The early 1970s saw psychedelics and psilocybin products made illegal in the US in the war on drugs. Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4%  and 20.6% of the adult population respectively. As psychedelics gain more recognition, companies such as Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF), Seelos Therapeutics (NASDAQ:SEEL), Numinus Wellness Inc. (TSXV:NUMI) (OTC:LKYSF), Mind Medicine (MindMed) (NASDAQ:MNMD) (NEO:MMED), and Mydecine Innovations Group Inc. (NEO:MYCO) (OTCPK:MYCOF) are engaging in research initiatives to develop psychedelic-assisted therapies for different mental illnesses and chronic pain conditions.

Key Points: 
  • Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.
  • Tryp will be collaborating with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School, a leading center in chronic pain research.
  • The upcoming Phase 2a trial is believed to be the world's first Phase 2 trial utilizing psilocybin for a chronic pain indication.
  • The clinical trial seeks to apply the neuroplasticity benefits of psilocybin to address the source of pain signals in fibromyalgia patients.

FDA Approves Octapharma’s Octagam® 10% for Adult Dermatomyositis

Tuesday, July 20, 2021 - 5:34pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210720005999/en/
    The U.S. Food and Drug Administration (FDA) has granted approval to Octapharma USA for Octagam 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease.
  • Dermatomyositis is a rare idiopathic autoimmune disorder of unknown cause affecting approximately 10 out of every million U.S. residents.
  • To learn more about Octagam 10% for the treatment of dermatomyositis, please click here .
  • 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis.